目的:肺癌(LC)是全球死亡率最高的恶性肿瘤,准确的早期诊断可以改善患者的预后。这项研究的目的是研究唾液蛋白中Hippeastrum杂合凝集素(HHL)识别的糖型模式的改变是否与LC的发展有关。
方法:首先,我们收集了来自LC(15例肺腺癌(ADC);15例鳞状细胞癌(SCC);15例小细胞肺癌(SCLC))和15例良性肺病(BPD)的唾液样本,用于使用蛋白质微阵列高通量检测HHL识别的糖模式的丰度水平。然后用凝集素印迹分析验证每组的合并样品。最后,使用MALDI-TOF/TOF-MS分别表征使用HHL-磁性颗粒缀合物从合并样品中分离的唾液糖蛋白的N-聚糖谱。
结果:结果表明,与BPD相比,LC中唾液蛋白中HHL识别的糖型丰度水平升高。ADC中甘露糖基化N-聚糖的比例明显较高(31.7%),SCC(39.0%),SCLC(46.6%)与BPD(23.3%)相比。
结论:改变的唾液糖型,如寡甘露糖,Manα1-3Man,或由HHL识别的Manα1-6ManN-聚糖可能作为诊断LC患者的潜在生物标志物。
结论:这项研究为研究唾液变化以区分BPD和LC提供了重要信息,并有助于发现基于唾液中甘露糖基化N-聚糖的精确改变的LC诊断生物标志物。
OBJECTIVE: Lung cancer (LC) is the malignant tumor with the highest mortality rate worldwide, and precise early diagnosis can improve patient prognosis. The purpose of this study was to investigate whether alterations in the glycopatterns recognized by the Hippeastrum hybrid lectin (HHL) in salivary proteins are associated with the development of LC.
METHODS: First, we collected saliva samples from LC (15 lung adenocarcinoma (ADC); 15 squamous cell carcinoma (SCC); 15 small cell lung cancer (SCLC)) and 15 benign pulmonary disease (BPD) for high-throughput detection of abundance levels of HHL-recognized glycopatterns using protein microarrays, and then validated the pooled samples from each group with lectin blotting analysis. Finally, the N-glycan profiles of salivary glycoproteins isolated from the pooled samples using HHL-magnetic particle conjugates were characterized separately using MALDI-TOF/TOF-MS.
RESULTS: The results showed that the abundance level of glycopatterns recognized by HHL in salivary proteins was elevated in LC compared to BPD. The proportion of mannosylated N-glycans was notably higher in ADC (31.7%), SCC (39.0%), and SCLC (46.6%) compared to BPD (23.3%).
CONCLUSIONS: The altered salivary glycopatterns such as oligomannose, Manα1-3Man, or Manα1-6Man N-glycans recognized by HHL might serve as potential biomarkers for the diagnosis of LC patients.
CONCLUSIONS: This study provides crucial information for studying changes in salivary to differentiate between BPD and LC and facilitate the discovery of biomarkers for LC diagnosis based on precise alterations of mannosylated N-glycans in saliva.